VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
- Conditions
- Advanced Melanoma
- Interventions
- Drug: Single-agent chemotherapy
- Registration Number
- NCT06264180
- Lead Sponsor
- Replimune Inc.
- Brief Summary
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 400
-
Male or female who is 12 years of age or older at the time of signed informed consent.
-
Patients with histologically or cytologically confirmed unresectable or metastatic Stage IIIb through IV/M1a through M1d cutaneous melanoma.
-
Confirmed disease progression (PD) on an approved anti-PD-1 and an anti-CTLA-4 treatment, administered either as a combination regimen (eg, nivolumab + ipilimumab) or in sequence.
- Treatment with prior anti-PD-1 therapy must have continued for a minimum of 8 weeks
- Patients who in the physician's judgement are not candidates for treatment with an anti-CTLA-4 antibody are eligible
-
Has documented BRAF V600 mutation status. Patients with BRAF mutation should have received prior BRAF-directed therapy (with or without a MEK inhibitor) prior to enrollment in the study, unless deemed not clinically indicated at Investigator's discretion due to concurrent medical condition or prior toxicity.
-
Has at least 1 measurable and injectable tumor of ≥1 cm in longest diameter (or shortest diameter for lymph nodes).
-
Has adequate hematologic function.
-
Has adequate hepatic function.
-
Has adequate renal function.
-
Prothrombin time (PT) ≤1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤1.5 × ULN
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1 for patients 18 years and older or a Lansky performance score (PSc) ≥80 for patients 12 to 17 years of age.
-
Life expectancy of at least 3 months.
-
Female and male patients of reproductive potential must agree to avoid becoming pregnant or impregnating a partner and adhere to highly effective contraception requirements during the treatment period and for at least 6 months after the last dose of study treatment.
-
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) test within 72 hours before the first dose of study treatment.
Key
- Primary mucosal or uveal melanoma.
- More than 2 lines of systemic therapy for advanced melanoma.
- Known acute or chronic hepatitis.
- Known human immunodeficiency virus (HIV) infection.
- Active significant herpetic infections or prior complications of HSV-1 infection.
- Had systemic infection requiring IV antibiotics or other serious active infection requiring antimicrobial, antiviral, or antifungal treatment within 14 days prior to dosing.
- With active significant herpetic infections or prior complications of HSV-1 infection.
- Evidence of spinal cord compression or at high risk of spinal cord compression.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis at time of screening.
- Serum lactate dehydrogenase (LDH) >2 × ULN.
- Major surgery ≤2 weeks prior to starting study drug.
- Prior malignancy active within the previous 3 years, except for locally curable cancers that have apparently been cured
- History of significant cardiac disease including myocarditis or congestive heart.
- History of life-threatening toxicity related to prior immune.
- Active, known, or suspected autoimmune disease requiring systemic treatment.
- History of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
- Prior oncolytic virus or other therapy given by intratumoral administration.
- Requires intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (eg, acyclovir).
- Has received a live vaccine within 28 days prior to the first dose of study treatment.
- Systemic anticancer therapies within 5 half-lives or 4 weeks of the first dose, whichever is shorter.
- Conditions requiring treatment with immunosuppressive doses (>10 mg per day of prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement therapy within 14 days after enrollment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description VO + nivolumab Vusolimogene Oderparepvec - Physicians Choice Nivolumab + Relatlimab Choosing from 1 of the following (to be consistent with approved label and/or applicable local clinical guidelines): * Nivolumab + relatlimab (as Opdualag) * Anti-PD-1 monotherapy (nivolumab or pembrolizumab) * Single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel) Physicians Choice Single-agent chemotherapy Choosing from 1 of the following (to be consistent with approved label and/or applicable local clinical guidelines): * Nivolumab + relatlimab (as Opdualag) * Anti-PD-1 monotherapy (nivolumab or pembrolizumab) * Single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel) VO + nivolumab Nivolumab - Physicians Choice Nivolumab Choosing from 1 of the following (to be consistent with approved label and/or applicable local clinical guidelines): * Nivolumab + relatlimab (as Opdualag) * Anti-PD-1 monotherapy (nivolumab or pembrolizumab) * Single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel) Physicians Choice Pembrolizumab Choosing from 1 of the following (to be consistent with approved label and/or applicable local clinical guidelines): * Nivolumab + relatlimab (as Opdualag) * Anti-PD-1 monotherapy (nivolumab or pembrolizumab) * Single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel)
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Assessed up to January 2029, approximately 55 months Time from the date of randomization to death due to any cause
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) Assessed up to January 2029, approximately 55 months The proportion of randomized patients with best overall response of complete response (CR) or partial response (PR) using the RECIST v1.1 criteria.
Progression Free Survival (PFS) Assessed up to January 2029, approximately 55 months The time from the date of randomization to the earliest date of the objective documentation of progressive disease (PD) per RECIST v1.1 or death due to any cause.
Trial Locations
- Locations (41)
Memorial Cancer Institute at Memorial Regional Hospital
🇺🇸Hollywood, California, United States
Sutter Medical Group
🇺🇸Sacramento, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Corewell Health
🇺🇸Grand Rapids, Michigan, United States
The Ohio State University- Martha Morehouse Tower
🇺🇸Columbus, Ohio, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
University of Vermont Medical Center
🇺🇸Burlington, Vermont, United States
UC San Diego Moores Cancer Center
🇺🇸La Jolla, California, United States
The Angeles Clinic and Research Institute
🇺🇸Los Angeles, California, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Scroll for more (31 remaining)Memorial Cancer Institute at Memorial Regional Hospital🇺🇸Hollywood, California, United StatesAtif Hussein, MDPrincipal Investigator